Generalized Cost-Effectiveness Analysis to Assess Treatment Value in Hepatitis C

This article estimates the comprehensive value of direct-acting antivirals for the treatment of hepatitis C virus using a generalized cost-effectiveness analysis.

Related Keywords

Canada ,United States ,Langley ,British Columbia ,Cuba ,Cuban ,American ,Hepat Mon ,Ray Kim ,Van Nuys ,Jacquelynw Chou ,Gastroenterol Hepatol ,Health Serv Res ,C Value Health ,Outcomes Research ,Lancet Glob Health ,Mark Cuban Cost Plus Drug Company ,Appl Health Econ ,Security Administration ,Bureau Of Economic Analysis ,Health Aff Millwood ,Precision Medicine Group ,Lancet Reg Health ,Federal Reserve Bank ,Institute For Clinical ,Society For Health Economics ,Value Health ,Bethesda Metro Center ,Forum Infect Dis ,Professional Society ,Health Economics ,Generalized Risk Adjusted Cost Effectiveness ,Economic Review ,Precision Medicine ,Metro Center ,Task Force ,Lancet Gastroenterol ,Evid Based ,American Association ,Mortal Wkly ,Health Econ ,Forum Infect ,Accessed November ,Accessed February ,Reg Health ,Comparative Clinical Effectiveness ,Novel Combination Therapies ,Patients With Genotype ,Thcv ,Hepatitis ,Cost Effectiveness ,